Cerbios-Pharma returns to DCAT17 with enhanced ADC and HPAI offers


Cerbios-Pharma returns to DCAT17 with enhanced ADC and HPAI offers


Cerbios Logo

Press Release | Cerbios-Pharma SA

MARCH 01, 2017

Lugano, Switzerland: Swiss-based high-potency API specialist Cerbios-Pharma SA (Cerbios) will use the high prestige DCAT Week in New York to showcase its exclusive contract manufacturing (CMO) services.

From two hotel suites in New York City, Cerbios will present the full range of its enhanced and innovative offers that include highly potent active ingredients (HPAIs), fully integrated Antibody Drug Conjugate (ADC) services through the PROVEO Alliance, modified antibodies (mAbs) and recombinant protein (Rec. Prot.) development.

Strategic meetings

Cerbios is inviting clients and contacts to its two suites available for meetings at the Lotte New York Palace Hotel, where teams will be led by Annalisa Miracca, Director Marketing and Sales of its Chemical Division and Simone Sala, Business Development Manager.

Cerbios CEO, Dr. Gabriel Haering, will also be present at DCAT Week to participate in discussions with key and potential customers as also with other companies about strategic alliances or cooperation.

“Before 2009, Cerbios was present only as visitor. Since 2009 we have an established presence at DCAT that has increased over time due to DCAT participants changes that includes more and more originators,” commented Dr. Gabriel Haering, CEO.

PROVEO Alliance

The Alliance established in 2016 integrates the competences of Cerbios and its partners CMC Biologics, Oncotec and IDT Biologika to offer a fully integrated service (more than a one-stop-shop) for the development and manufacture of ADC Drug Substance and Drug Product.
“This is a superb event for forging and extending our contacts with the pharmaceutical industry in North America and Europe and presenting the wider range of very interesting services we can now offer,” said Mr. Simone Sala.

Delegates from PROVEO members will also be present at this event and available to schedule meetings with potential customers. To fix an appointment contact Ms. Chiara Brusadelli, chiara.brusadelli@cerbios.ch.

About Cerbios-Pharma

Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners worldwide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.

Cerbios Chemical Division offers exclusive, third party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.

Since 2016, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with CMC Biologics of Denmark, together with Germany’s Oncotec and IDT Biologika. PROVEO can offer a one-stop shop service from substance development through to fill and finish.

About DCAT Week 2017

The Drug, Chemical & Associated Technologies Association (DCAT), founded in 1890, has become North America’s premier business development association for companies that manufacture, distribute or provide services to the pharmaceutical and chemical industries. DCAT represents the entire spectrum of the pharmaceutical industry from pharmaceutical, API, and excipient sales and manufacturing to distribution, support technologies and packaging products and services.

Attended by thousands of industry professionals, DCAT Week® and the DCAT Annual Dinner, held each March in New York City, are considered one of the pharma industry’s premier events.

DCAT Week 2017 will take place over four days from March 20 to March 23. Renovation at Waldorf Astoria has meant that the event’s traditional headquarters is unavailable this year, with activities shared between seven other downtown hotels including the Lotte New York Palace, Omni Berkshire Place, 48LEX, Benjamin and InterContinental Barclay, with the 91st DCAT Annual Dinner held in the Grand Ballroom of the New York Hilton on Thursday, March 23.

The event is organized by DCAT with more information at: https://www.dcat.org/

Media Contact

Chiara Brusadelli, Commercial Operations Assistant Manager, Cerbios-Pharma SA
Tel: +41 91 9856311
Email: chiara.brusadelli@cerbios.ch

Resources

Click on Cerbios-Pharma returns to DCAT17 for more information.
Click on Cerbios-Pharma to contact the company directly.
Click on PROVEO to learn more about the ADC Alliance.

Cerbios is equipped to manufacture high potency active ingredients under high containment

Cerbios is equipped to manufacture high potency active ingredients under high containment

Cerbios offers a range of advanced ADC, modified antibodies and other manufacturing services

Cerbios offers a range of advanced ADC, modified antibodies and other manufacturing services

Cerbios CEO Dr. Gabriel Haering

Cerbios CEO Dr. Gabriel Haering


Supplier Information
Supplier: Cerbios-Pharma SA
Address: Via Figino 6, 6917 Barbengo/Lugano Switzerland
Tel: +41 (0) 919856311
Fax: +41 (0) 919856325
Website: www.cerbios.ch


Comments are closed.